Dynamics of the Volterra-type integral and differentiation operators on generalized Fock spaces

[EN] Various dynamical properties of the differentiation and Volterra-type integral operators on generalized Fock spaces are studied. We show that the differentiation operator is always supercyclic on these spaces. We further characterize when it is hypercyclic, power bounded and uniformly mean ergodic. We prove that the operator satisfies the Ritt's resolvent condition if and only if it is power bounded and uniformly mean ergodic. Some similar results are obtained for the Volterra-type and Hardy integral operators.J. Bonet was partially supported by the research projects MTM2016-76647-P and GV Prometeo 2017/102 (Spain). M. Worku is supported by ISP project, Addis Ababa University, Ethiopia.Bonet Solves, JA.; Mengestie, T.; Worku, M. (2019). Dynamics of the Volterra-type integral and differentiation operators on generalized Fock spaces. Results in Mathematics. 74(4):1-15. https://doi.org/10.1007/s00025-019-1123-7S115744Abanin, A.V., Tien, P.T.: Differentiation and integration operators on weighted Banach spaces of holomorphic functions. Math. Nachr. 290(8–9), 1144–1162 (2017)Atzmon, A., Brive, B.: Surjectivity and invariant subspaces of differential operators on weighted Bergman spaces of entire functions, Bergman spaces and related topics in complex analysis, Contemp. Math., vol. 404, Amer. Math. Soc., Providence, RI, pp. 27–39 (2006)Bayart, F., Matheron, E.: Dynamics of Linear Operators, Cambridge Tracts in Math, vol. 179. Cambridge Univ. Press, Cambridge (2009)Bermúdez, T., Bonilla, A., Peris, A.: On hypercyclicity and supercyclicity criteria. Bull. Austral. Math. Soc. 70, 45–54 (2004)Beltrán, M.J.: Dynamics of differentiation and integration operators on weighted space of entire functions. Studia Math. 221, 35–60 (2014)Beltrán, M.J., Bonet, J., Fernández, C.: Classical operators on weighted Banach spaces of entire functions. Proc. Am. Math. Soc. 141, 4293–4303 (2013)Bès, J., Peris, A.: Hereditarily hypercyclic operators. J. Funct. Anal. 167, 94–112 (1999)Bonet, J.: Dynamics of the differentiation operator on weighted spaces of entire functions. Math. Z. 26, 649–657 (2009)Bonet, J.: The spectrum of Volterra operators on weighted Banach spaces of entire functions. Q. J. Math. 66, 799–807 (2015)Bonet, J., Bonilla, A.: Chaos of the differentiation operator on weighted Banach spaces of entire functions. Complex Anal. Oper. Theory 7, 33–42 (2013)Bonet, J., Taskinen, J.: A note about Volterra operators on weighted Banach spaces of entire functions. Math. Nachr. 288, 1216–1225 (2015)Constantin, O., Persson, A.-M.: The spectrum of Volterra-type integration operators on generalized Fock spaces. Bull. Lond. Math. Soc. 47, 958–963 (2015)Constantin, O., Peláez, J.-Á.: Integral operators, embedding theorems and a Littlewood–Paley formula on weighted Fock spaces. J. Geom. Anal. 26, 1109–1154 (2016)De La Rosa, M., Read, C.: A hypercyclic operator whose direct sum is not hypercyclic. J. Oper. Theory 61, 369–380 (2009)Dunford, N.: Spectral theory. I. Convergence to projections. Trans. Am. Math. Soc. 54, 185–217 (1943)Grosse-Erdmann, K.G., Peris Manguillot, A.: Linear Chaos. Springer, New York (2011)Harutyunyan, A., Lusky, W.: On the boundedness of the differentiation operator between weighted spaces of holomorphic functions. Studia Math. 184, 233–247 (2008)Krengel, U.: Ergodic Theorems. Walter de Gruyter, Berlin (1985)Lyubich, Yu.: Spectral localization, power boundedness and invariant subspaces under Ritt’s type condition. Studia Mathematica 143(2), 153–167 (1999)Mengestie, T.: A note on the differential operator on generalized Fock spaces. J. Math. Anal. Appl. 458(2), 937–948 (2018)Mengestie, T.: Spectral properties of Volterra-type integral operators on Fock–Sobolev spaces. J. Kor. Math. Soc. 54(6), 1801–1816 (2017)Mengestie, T.: On the spectrum of volterra-type integral operators on Fock–Sobolev spaces. Complex Anal. Oper. Theory 11(6), 1451–1461 (2017)Mengestie, T., Ueki, S.: Integral, differential and multiplication operators on weighted Fock spaces. Complex Anal. Oper. Theory 13, 935–95 (2019)Mengestie, T., Worku, M.: Isolated and essentially isolated Volterra-type integral operators on generalized Fock spaces. Integr. Transf. Spec. Funct. 30, 41–54 (2019)Nagy, B., Zemanek, J.A.: A resolvent condition implying power boundedness. Studia Math. 134, 143–151 (1999)Nevanlinna, O.: Convergence of iterations for linear equations. Lecture Notes in Mathematics. ETH Zürich, Birkhäuser, Basel (1993)Ritt, R.K.: A condition that $$\lim _{n\rightarrow \infty } n^{-1}T^n =0$$. Proc. Am. Math. Soc. 4, 898–899 (1953)Ueki, S.: Characterization for Fock-type space via higher order derivatives and its application. Complex Anal. Oper. Theory 8, 1475–1486 (2014)Yosida, K.: Functional Analysis. Springer, Berlin (1978)Yosida, K., Kakutani, S.: Operator-theoretical treatment of Marko’s process and mean ergodic theorem. Ann. Math. 42(1), 188–228 (1941

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402

Validation of the use of multiple internal control genes, and the application of real-time quantitative PCR, to study esterase gene expression in Oenococcus oeni

The study of gene expression and accurate quantitation of target genes in any organism depends on correct normalisation. Due to the increase in studies on Oenococcus oeni gene expression, there is a clear need for alternative reference genes in order to reliably measure expression levels. In this manuscript, we propose the approach of using multiple reference genes to provide a more robust basis for establishing a reference gene set. The identification and evaluation of a panel of nine reference genes, including the commonly used ldhD, for real-time PCR normalisation was performed in O. oeni. Expression levels of these reference genes were then measured by real-time qPCR in an independent set of O. oeni samples (n = 30). The nine genes were ranked according to their stability of gene expression measure (M) using geNorm to identify the most consistently expressed reference genes. This approach resulted in the identification of multiple reference genes that may be used for a screening and more robust normalisation of target gene expression measured by real-time RT-qPCR. Expression of esterase genes was then measured in these O. oeni samples in the presence of known esterase substrates. The results give an indication of how these genes may be involved in ester synthesis and hydrolysis in O. oeni.Krista M. Sumby, Paul R. Grbin, Vladimir Jirane